LT3434760T - Metodai, skirti padidinti rekombinantinių baltymų manozės kiekį - Google Patents

Metodai, skirti padidinti rekombinantinių baltymų manozės kiekį

Info

Publication number
LT3434760T
LT3434760T LTEP18194714.4T LT18194714T LT3434760T LT 3434760 T LT3434760 T LT 3434760T LT 18194714 T LT18194714 T LT 18194714T LT 3434760 T LT3434760 T LT 3434760T
Authority
LT
Lithuania
Prior art keywords
methods
recombinant proteins
mannose content
increasing
increasing mannose
Prior art date
Application number
LTEP18194714.4T
Other languages
English (en)
Inventor
Jian Wu
Sean Davern
Simina PETROVAN
Michael BRANDENSTEIN
Katherine LINDAHL
Shawn LILLIE
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50397323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3434760(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of LT3434760T publication Critical patent/LT3434760T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
LTEP18194714.4T 2013-03-14 2014-03-10 Metodai, skirti padidinti rekombinantinių baltymų manozės kiekį LT3434760T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361784639P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
LT3434760T true LT3434760T (lt) 2022-06-27

Family

ID=50397323

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP14714521.3T LT2970874T (lt) 2013-03-14 2014-03-10 Manozės kiekio rekombinantiniuose baltymuose padidinimo būdas
LTEP18194714.4T LT3434760T (lt) 2013-03-14 2014-03-10 Metodai, skirti padidinti rekombinantinių baltymų manozės kiekį

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP14714521.3T LT2970874T (lt) 2013-03-14 2014-03-10 Manozės kiekio rekombinantiniuose baltymuose padidinimo būdas

Country Status (18)

Country Link
US (6) US9822388B2 (lt)
EP (3) EP2970874B1 (lt)
AR (1) AR095418A1 (lt)
CY (1) CY1120824T1 (lt)
DK (2) DK3434760T3 (lt)
ES (2) ES2949507T3 (lt)
FI (1) FI3434760T3 (lt)
HR (1) HRP20230667T1 (lt)
HU (2) HUE040682T2 (lt)
LT (2) LT2970874T (lt)
PL (2) PL2970874T3 (lt)
PT (2) PT2970874T (lt)
RS (1) RS64326B1 (lt)
SI (2) SI2970874T1 (lt)
SM (1) SMT202300199T1 (lt)
TR (1) TR201815892T4 (lt)
TW (4) TWI771890B (lt)
WO (1) WO2014159259A1 (lt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI120045B (fi) 2005-12-22 2009-06-15 Roal Oy Selluloosamateriaalin käsittely ja siinä käyttökelpoiset entsyymit
DK2726600T3 (en) 2011-07-01 2017-05-15 Amgen Inc Mammalian Cell Culture
US10059770B2 (en) 2012-01-30 2018-08-28 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of a glycoprotein composition
TWI771890B (zh) 2013-03-14 2022-07-21 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
HUE071397T2 (hu) * 2013-10-31 2025-08-28 Amgen Inc Monenzin alkalmazása rekombináns fehérjék glikozilációjának szabályozására
WO2017044811A1 (en) * 2015-09-11 2017-03-16 Bruce Andrien Recombinant glycosylated eculizumab and eculizumab variants
AU2016374304A1 (en) * 2015-12-15 2018-06-14 CSL Behring Lengnau AG Method for increasing the heterogeneity of O-glycosylation of recombinant factor VII
WO2018157072A1 (en) * 2017-02-27 2018-08-30 Life Technologies Corporation Expansion of populations of t cells by the use of modified serum free media
KR20200083564A (ko) * 2017-11-13 2020-07-08 암젠 인크 단백질 산물을 제조하는 방법
US11566062B2 (en) 2017-12-20 2023-01-31 Ares Trading S.A. Methods for modulating protein mannosylation profiles using maduramycin, narasin, or salinomycin
BR112020019559A2 (pt) 2018-03-26 2021-01-12 Amgen Inc. Glicoformas afucosiladas totais de anticorpos produzidos em cultura de células
IL321253A (en) * 2018-05-01 2025-08-01 Amgen Inc Antibodies with a modulated glycan profile
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
ATE194384T1 (de) 1989-09-12 2000-07-15 Hoffmann La Roche Tnf-bindende proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
ATE240394T1 (de) 1992-10-23 2003-05-15 Immunex Corp Methoden zur herstellung löslicher, oligomerer proteine
JPH06292592A (ja) * 1993-02-09 1994-10-21 Snow Brand Milk Prod Co Ltd 糖蛋白質の生産方法
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
AU708239B2 (en) 1995-06-29 1999-07-29 Immunex Corporation Cytokine that induces apoptosis
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ES2252876T5 (es) * 1997-12-03 2014-04-03 Roche Diagnostics Gmbh Proceso para preparar polipéptidos con glicolización adecuada
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
CA2492267C (en) 2002-07-15 2013-09-10 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
DE60335024D1 (de) * 2002-12-23 2010-12-30 Bristol Myers Squibb Co Produktqualitätsverbesserung in säugerzellkulturverfahrenzur proteinproduktion
DE102005046225B4 (de) 2005-09-28 2012-01-05 Cellca Gmbh Verbessertes Zellkulturmedium
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
US9034341B2 (en) 2009-04-20 2015-05-19 Transtech Pharma, Llc Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
US20120164137A1 (en) 2010-10-20 2012-06-28 Morphotek, Inc. Anti-folate receptor alpha antibody glycoforms
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
EP2702077A2 (en) * 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
DK2726600T3 (en) * 2011-07-01 2017-05-15 Amgen Inc Mammalian Cell Culture
TWI771890B (zh) 2013-03-14 2022-07-21 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US9481901B2 (en) * 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins

Also Published As

Publication number Publication date
SI2970874T1 (sl) 2019-01-31
US20230193340A1 (en) 2023-06-22
TW201831677A (zh) 2018-09-01
US11319568B2 (en) 2022-05-03
PL2970874T3 (pl) 2019-03-29
US11952605B2 (en) 2024-04-09
US20200087698A1 (en) 2020-03-19
AR095418A1 (es) 2015-10-14
TW202311525A (zh) 2023-03-16
TWI625390B (zh) 2018-06-01
HRP20230667T1 (hr) 2023-10-13
ES2691801T3 (es) 2018-11-28
LT2970874T (lt) 2018-12-10
TWI720289B (zh) 2021-03-01
SMT202300199T1 (it) 2023-09-06
TWI771890B (zh) 2022-07-21
EP4141104A1 (en) 2023-03-01
RS64326B1 (sr) 2023-08-31
US20220213522A1 (en) 2022-07-07
TW201441368A (zh) 2014-11-01
EP2970874B1 (en) 2018-09-19
FI3434760T3 (fi) 2023-06-12
HUE040682T2 (hu) 2019-03-28
US20220136026A1 (en) 2022-05-05
US11459595B2 (en) 2022-10-04
US9822388B2 (en) 2017-11-21
EP2970874A1 (en) 2016-01-20
SI3434760T1 (sl) 2022-08-31
DK2970874T3 (en) 2018-11-19
ES2949507T3 (es) 2023-09-29
PT2970874T (pt) 2018-11-16
CY1120824T1 (el) 2019-12-11
TWI832345B (zh) 2024-02-11
HUE063435T2 (hu) 2024-01-28
US20160032343A1 (en) 2016-02-04
PL3434760T3 (pl) 2023-09-11
PT3434760T (pt) 2022-07-05
WO2014159259A1 (en) 2014-10-02
EP3434760B1 (en) 2023-04-26
DK3434760T3 (da) 2023-07-24
EP3434760A1 (en) 2019-01-30
TR201815892T4 (tr) 2018-11-21
TW202142685A (zh) 2021-11-16
US20180002733A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
IL281703A (en) New heterodimeric proteins
SI3434760T1 (sl) Postopki za povečanje vsebnosti manoze v rekombinantnih proteinih
SG11201510747RA (en) Method for increasing expression of rna-encoded proteins
SG11201506876XA (en) Modification of polypeptides
SG11201603028SA (en) Purification of proteins
PL2986633T3 (pl) Sposoby ekspresji peptydów i białek
IL268868B (en) A new method for protein purification
SG10201802109SA (en) Method of extracting protein
GB201304973D0 (en) Recombinant protein
IL240639A0 (en) Formulations and methods for increased recombinant production of protein
IL241248A0 (en) Enhanced expression of pico-rnavirus proteins
IL235052A0 (en) A method for increasing the secretion of recombinant proteins
SG11201505941PA (en) Cytoplasmic expression of fab proteins
GB201308120D0 (en) Recombinant protein and method for its production
EP2978770A4 (en) REINFORCEMENT OF PROTEINS
SG11201600380VA (en) Apparatus for refolding of recombinant proteins
GB201321911D0 (en) N-Glycosylation of peptides and proteins
GB201318313D0 (en) N-Glycosylation of peptides and proteins